Jazz Pharmaceuticals (JAZZ) Stock: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$211.97
-1.79 (-0.84%)
▼
5d:
+1.11%
30d:
-11.89%
90d:
-16.83%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 02, 2026
10d
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAZZ shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: JAZZ shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$417.01
Based on 13.7% avg growth
INTRINSIC VALUE TODAY
$258.93
18.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $211.97, which is considered oversold relative to its 30-day fair value range of $216.73 to $241.26. The stock's valuation (Forward PE: 8.1) is in line with its historical norms (8.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This pessimistic expectation contrasts with the company's recent 3.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, JAZZ is showing sideways momentum. The price is currently testing key support at $206.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $294.64 (+39.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAZZ is showing sideways momentum. The price is currently testing key support at $206.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 57/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $294.64 (+39.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$216.73 -
$241.26
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
Protect Your Profits
Holding JAZZ? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (57/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.0% below Wall St target ($294.64)
- NEUTRAL: Bottoming setup forming (57/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$216.73 -
$241.26
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$10.73
(5.1%)
Support & Resistance Levels
Support Level
$206.71
Resistance Level
$229.33
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.14
Wall Street Target
$294.64
(+39.0%)
Revenue Growth (YoY)
15.5%
Earnings Growth (YoY)
3.2%
Profit Margin
20.4%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
8.1 vs 8.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$209.00
(-1%)
2-Year Target
$206.08
(-3%)
3-Year Target
$203.19
(-4%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$212.29
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 23.4%)
$972.11
(+359%)
Base:
(SPY PE: 8.1, Growth: 23.4%)
$398.22
(+88%)
Bear:
(PE: 6.9, Growth: 23.4%)
$338.48
(+60%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 14.65 | Current EPS (TTM): $14.59
Bull Case
$419.91
(+98%)
Analyst growth 78.6%, PE expands to 16.1
Base Case
$381.73
(+80%)
Market implied 78.6%, PE stable at 14.7
Bear Case
$145.36
(-31%)
Severe decline -20.0%, PE contracts to 12.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.1 to 8.5
Stabilization Target:
$221.47
(+4.5%)
PE Expansion Potential:
+4.5%
Share & Embed Analysis
Last updated: October 22, 2026 7:05 AM ET
Data refreshes hourly during market hours. Next update: 8:05 AM
Data refreshes hourly during market hours. Next update: 8:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 70 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 71 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 51 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
